Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients

Israel Medical Association Journal

Volumn 17, Issue 1, 2015, Pages 5-10

  Martínez Godínez, Maria A ^a   Cruz Domínguez, Maria del Pilar ^b,e   Jara, Luis J ^c,e   Domínguez López, Aarón ^a   Jarillo Luna, Rosa A ^a   Vera Lastra, Olga ^b,e   Montes Cortes, Daniel H ^b   Campos Rodríguez, Rafael ^a   López Sánchez, Dulce M ^a   Mejía Barradas, Cesar M ^a   Castelán Chávez, Enrique E ^d   Miliar García, Angel ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b Department of Internal Medicine Antonio Fraga Mouret National Medical Center   (Mexico)

^c Centro Medical National la Raza   (Mexico)

^d Hospital Infantil de México Federico Gómez   (Mexico)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Caspase 1; Inflammasome; NLRP3; Skin; Systemic sclerosis (SSc)

Indexed keywords

CRYOPYRIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 33; TRANSFORMING GROWTH FACTOR BETA; AUTACOID; CARRIER PROTEIN; CYTOKINE; NLRP3 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SKIN BIOPSY; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; BIOPSY; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; SKIN;

ADULT; BIOPSY; CARRIER PROTEINS; CYTOKINES; ENDOTHELIN-1; FEMALE; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMASOMES; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SKIN;

EID: 84921866275     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
2. Furst DE, Clements PJ, Steen VD, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998; 25: 84-8.
3. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998; 110: 47-51.
4. Kawaguchi Y, Suzuki K, Hara M, et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994; 53: 506-10.
5. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117: 524-9.
6. Artlett CM, Sassi-Gaha S, Rieger JL, Boesteanu AC, Feghali-Bostwick CA, Katsikis PD. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum 2011; 63: 3563-74.
7. Pedra JH, Cassel SL, Sutterwala FS. Sensing pathogens and danger signals by the inflammasome. Curr Opin Immunol 2009; 21: 10-16.
8. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009; 10: 241-7.
9. Jha S, Srivastava SY, Brickey WJ, et al. The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J Neurosci 2010; 30: 15811-20.
10. Gasse P, Riteau N, Charron S, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009; 179: 903-13.
11. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
12. Medsger T, Silman A, Steen V, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 59-67.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8.
14. Winer J, Jung CK, Shackel I, Williams PM. Development and validation of realtime quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 1999; 270: 41-9.
15. Haneklaus M, O'Neill LAJ, Coll RC. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr Opin Immunol 2013; 25: 40-5.
16. Ishibuchi H, Abe M, Yokoyama Y, Ishikawa O. Induction of matrix metalloproteinase-1 by small interfering RNA targeting connective tissue growth factor in dermal fibroblasts from patients with systemic sclerosis. Exp Dermatol 2010; 19: e111-16.
17. Ihn H. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 2008; 49: 103-13.
18. Igarashi A, Nashiro K, Kikuchi K, et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995; 105: 280-4.
19. Sato S, Nagaoka T, Hasegawa M, et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000; 27: 149-54.
20. Dziadzio M, Smith RE, Abraham DJ, Black CM, Denton CP. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) 2005; 44: 1518-24.
21. Sulli A, Soldano S, Pizzorni C, et al. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J Rheumatol 2009; 36: 1235-9.
22. Matucci Cerinic M, Kahaleh MB. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology (Oxford) 2002; 41: 843-7.
23. Sambo P, Baroni SS, Luchetti M, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001; 44: 2653-64.
24. Cruz-Dominguez MP, Montes-Cortes DH, Olivares-Corichi IM, Vera-Lastra O, Medina G, Jara LJ. Oxidative stress in Mexicans with diffuse cutaneous systemic sclerosis. Rheumatol Int 2013; 33: 2261-7.
25. Kuhn A, Haust M, Ruland V, et al. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford) 2010; 49: 1336-45.